Alcon (XSWX:ALCE) Marketable Securities: CHF64 Mil (As of Mar. 2026)


XSWX:ALCE Alcon Inc XSWX:ALCE
53 GF Score
Price CHF55.60
GF Value CHF73.46
Valuation Modestly Undervalued
! 3 Warning Signs
View Full Analysis

What is Alcon Marketable Securities?

Alcon XSWX:ALCE +3.65% 53 Marketable Securities is CHF64 Mil as of Mar. 2026. GuruFocus rates XSWX:ALCE with a GF Score™ of 53/100 and a GF Value™ of CHF73.46 (Modestly Undervalued). The stock has 3 warning signs investors should review.

Marketable Securities are very liquid securities that can be converted into cash quickly at a reasonable price. Alcon's Marketable Securities for the quarter that ended in Mar. 2026 was CHF64 Mil.

Alcon's annual Marketable Securities declined from Dec. 2023 (CHF6 Mil) to Dec. 2024 (CHF0 Mil) but then stayed the same from Dec. 2024 (CHF0 Mil) to Dec. 2025 (CHF0 Mil).

Alcon  (XSWX:ALCE) Marketable Securities Explanation

Marketable Securities are very liquid as they tend to have maturities of less than one year. Furthermore, the rate at which these securities can be bought or sold has little effect on their prices.

Please note, GuruFocus' Marketable Securities also includes "Other Short Term Investment".

Alcon Marketable Securities Related Terms

Alcon Marketable Securities Historical Data

* Premium members only.

The historical data trend for Alcon's Marketable Securities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Alcon Marketable Securities Chart

Alcon Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Marketable Securities
Get a 7-Day Free Trial Premium Member Only Premium Member Only 2.76 0.00 6.05 0.00 0.00

Alcon Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Marketable Securities Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 63.77
XSWX:ALCE
53GF Score
Alcon Inc XSWX:ALCE
Marketable Securities is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Alcon Marketable Securities Calculation

Marketable Securities are very liquid securities that can be converted into cash quickly at a reasonable price.

Frequently Asked Questions Learn more about Marketable Securities →
What does a Marketable Securities of CHF64 Mil mean?
Alcon (XSWX:ALCE) has a Marketable Securities of CHF64 Mil as of Mar. 2026. Marketable securities are high-liquid securites not directly classified as cash or cash equivalents. View historical data on Alcon and its competitors.
Is Alcon's Marketable Securities too high?
Alcon's current Marketable Securities is CHF64 Mil. Overall, Alcon has a GF Score™ of 53/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Alcon's Marketable Securities compare to ISRG and BDX?
Alcon's Marketable Securities of CHF64 Mil can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Marketable Securities for a Medical Devices & Instruments company?
A good Marketable Securities depends on the Medical Devices & Instruments industry context. However, Marketable Securities should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Marketable Securities mean?
A high Marketable Securities can signal that a stock is expensive relative to its fundamentals. Marketable securities are high-liquid securites not directly classified as cash or cash equivalents. View historical data on Alcon and its competitors. Alcon's current Marketable Securities is CHF64 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Alcon stock overvalued right now?
Based on GuruFocus' analysis, Alcon (XSWX:ALCE) is currently considered Modestly Undervalued. The stock's GF Value™ is CHF73.46, compared to a current price of CHF55.60 — trading 24.3% below its estimated fair value. The current Marketable Securities is CHF64 Mil. Alcon's overall GF Score™ is 53/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Marketable Securities calculated?
Marketable Securities is calculated from a company's financial statements. For Alcon (XSWX:ALCE), the current Marketable Securities is CHF64 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Alcon (XSWX:ALCE) Overvalued in 2026?

Based on GuruFocus' analysis, Alcon stock appears to be undervalued. The current stock price of CHF55.60 is trading 24.3% below its estimated GF Value™ of CHF73.46. GuruFocus considers Alcon to be Modestly Undervalued.

Key valuation signals for XSWX:ALCE:

  • Marketable Securities: CHF64 Mil
  • GF Value™: CHF73.46 vs. price of CHF55.60 (24.3% below fair value)
  • GF Score™: 53/100 with 3 warning signs

No single metric tells the full story. See the XSWX:ALCE stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Alcon Business Description

Address Chemin de Blandonnet 8, Vernier, Geneva, CHE, 1214
Alcon is one of the leading visioncare companies in the world. Following nine years as a Novartis subsidiary, it was spun off as a public company in April 2019. Alcon operates in two segments: visioncare and surgical. Visioncare comprises contact lenses, lenscare solutions, and a suite of ocular health products. With brands like Dailies, Total1, and Air Optix, Alcon controls about one fourth of the US contact lens market. Surgical comprises intraocular lenses, ophthalmic surgical equipment, and consumables used during surgeries. Its main products include Centurion, a phacoemulsification device used during cataract surgeries, and a portfolio of IOLs including PanOptix and Vivity. Alcon has one of the largest installed bases of eye surgical equipment in the world.
53GF Score

Get the complete analysis for XSWX:ALCE

Marketable Securities is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

CHF55.60
Price
CHF73.46
GF Value